Shattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average PT from Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $4.00.

A number of equities analysts recently weighed in on the stock. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, December 1st. Citigroup increased their price target on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a research note on Wednesday, October 8th.

Shattuck Labs Stock Up 3.8%

STTK traded up $0.17 during midday trading on Friday, hitting $4.64. 485,596 shares of the company were exchanged, compared to its average volume of 617,574. The firm has a market capitalization of $293.62 million, a P/E ratio of -4.55 and a beta of 1.53. The firm’s 50 day moving average price is $3.07 and its 200-day moving average price is $2.03. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $4.89.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $1.00 million during the quarter. On average, sell-side analysts predict that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Orbimed Advisors LLC bought a new stake in shares of Shattuck Labs during the third quarter valued at approximately $15,072,000. Bank of America Corp DE lifted its holdings in shares of Shattuck Labs by 2,968.2% in the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after purchasing an additional 1,094,997 shares in the last quarter. Aberdeen Group plc grew its position in Shattuck Labs by 462.1% in the 4th quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock valued at $1,939,000 after purchasing an additional 436,673 shares during the period. Two Sigma Investments LP increased its stake in Shattuck Labs by 431.1% during the 3rd quarter. Two Sigma Investments LP now owns 408,598 shares of the company’s stock valued at $977,000 after purchasing an additional 331,664 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in Shattuck Labs by 2,510.8% during the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock worth $229,000 after buying an additional 278,576 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.